Prostate Cancer Linked to Zantac
Call Our Defective Drug Attorneys in New York for a Free Consultation
In October of 2019, Zantac and other similar ranitidine-containing antacids were recalled throughout North America. The main reason for this recall was the discovery that Zantac and other ranitidine medications contained higher than acceptable levels of N-nitrosodimethylamine, or NDMA, a type of N-nitroso compound (NOC) and known carcinogen. In relation to this, Zantac has been linked to numerous types of cancer, including prostate cancer. In fact, several studies have shown a direct connection between NDMA exposure and prostate cancer.
Were you or a loved one diagnosed with prostate cancer after taking Zantac or a similar over-the-counter or prescription ranitidine medication? You could be eligible to seek compensation for your damages by filing a Zantac lawsuit—and our firm can help. Rheingold Giuffra Ruffo & Plotkin LLP is highly experienced in defective drug claims, including those involving Zantac. Our New York Zantac lawsuit lawyers are prepared to take on national and global pharmaceutical manufacturers and pursue the just compensation you are owed.
To learn more, including whether you have grounds for a claim, contact us online or call (888) 260-0473 today for a free, confidential consultation.
NDMA Exposure Linked to Prostate Cancer
As previously mentioned, several recent studies have demonstrated a link between exposure to NDMA and prostate cancer. Studies conducted by the Institut National De Santé Publique Du Québec, the Institute of Epidemiology and Social Medicine (University of Münster, Germany), and others have looked at the connection between workplace exposure to NDMA within the rubber industry and prostate cancer. Numerous studies have reported an increase in the frequency of prostate cancer in relation to environmental NDMA exposure.
It is, therefore, unsurprising that prostate cancer has also been linked to Zantac and other ranitidine medications. Ranitidine, the active ingredient in Zantac, has been shown to create NDMA as a natural byproduct after ingestion. As a result, those who take Zantac or other ranitidine medications for extended periods of time are more likely to be exposed to higher levels of NDMA, leading to various forms of cancer growth, including prostate cancer.
Contact Rheingold Giuffra Ruffo & Plotkin LLP Today
Prostate cancer is one of the most aggressive and deadliest forms of cancer, second only to skin cancer (melanoma) in malignant frequency among males. If you or someone you love was diagnosed with prostate cancer after long-term use of Zantac or another ranitidine medication, our New York defective drug attorneys can help you seek the justice and compensation you and your family deserve. We are committed to guiding our clients through every stage of the legal process and have a proven record of results. Learn more about Zantac litigation here on our website, or reach out to us directly for a free initial consultation.
Call us at (888) 260-0473 or contact us online. Your initial consultation is completely free, and we do not collect any attorneys’ fees unless we recover compensation on your behalf.